Evaluation of the safety and efficacy of corifollitropin alfa combined with GnRH agonist triggering in oocyte donation cycles. A prospective longitudinal study

Ioannis Tsakiridis, Robert Najdecki, Petroula Tatsi, Evi Timotheou, Kallirhoe Kalinderi, Georgios Michos, Andriana Virgiliou, Hakan Yarali, Apostolos Athanasiadis, Evangelos G Papanikolaou, Ioannis Tsakiridis, Robert Najdecki, Petroula Tatsi, Evi Timotheou, Kallirhoe Kalinderi, Georgios Michos, Andriana Virgiliou, Hakan Yarali, Apostolos Athanasiadis, Evangelos G Papanikolaou

Abstract

Objective: In order to help make the dream of parenthood come true for oocyte acceptors, it is essential that the procedure is not dangerous or unpleasant for oocyte donors. The aim of this study was to identify differences in safety, efficacy and patient acceptability between a traditional stimulation antagonist protocol with recombinant-FSH (rFSH) with hCG-triggering, compared with an innovative antagonist protocol with corifollitropin alfa (Elonva®) plus GnRH agonist triggering in oocyte donors.

Methods: A prospective longitudinal study was conducted at an in vitro fertilization center in Greece. The same eighty donors underwent two consecutive antagonist stimulation schemes. Primary outcomes were patient satisfaction (scored by a questionnaire) and delivery rate per donor. Secondary outcomes were mean number of cumulus-oocyte-complexes, metaphase II (MII) oocytes and ovarian hyperstimulation syndrome (OHSS) rate.

Results: Donors reported better adherence and less discomfort with the corifollitropin alpha + GnRH agonist-triggering protocol (p<0.001). No significant differences were identified in the clinical pregnancy rate per donor (p=0.13), the delivery rates, the number of oocytes (p=0.35), the number of MII oocytes (p=0.50) and the number of transferred embryos, between the two protocols. However, the luteal phase duration was significantly shorter (p<0.001) in the corifollitropin alpha + GnRH agonist-triggering protocol. Moreover, three cases of moderate OHSS (3.75%) were identified after hCG triggering, whereas no case of OHSS occurred after GnRH agonist ovulation induction (p=0.25).

Conclusion: The use of corifollitropin alpha combined with a GnRH agonist for triggering is a safe, effective and acceptable protocol for oocyte donors.

Keywords: GnRH agonist triggering; IVF; corifollitropin alfa; donor; oocyte donation.

Conflict of interest statement

CONFLICT OF INTEREST

The authors have no conflict of interest to declare.

References

    1. Acevedo B, Gomez-Palomares JL, Ricciarelli E, Hernandez ER. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates. Fertil Steril. 2006;86:1682–1687. doi: 10.1016/j.fertnstert.2006.05.049.
    1. Al-Inany HG, Youssef MA, Ayeleke RO, Brown J, Lam WS, Broekmans FJ. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2016;4:CD001750–CD001750. doi: 10.1002/14651858.CD001750.pub4.
    1. Bodri D, Guillén JJ, Galindo A, Mataró D, Pujol A, Coll O. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study. Fertil Steril. 2009;91:365–371. doi: 10.1016/j.fertnstert.2007.11.049.
    1. Boostanfar R, Shapiro B, Levy M, Rosenwaks Z, Witjes H, Stegmann BJ, Elbers J, Gordon K, Mannaerts B, Pursue investigators Large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist controlled ovarian stimulation protocol in older patients undergoing in vitro fertilization. Fertil Steril. 2015;104:94–103.e1. doi: 10.1016/j.fertnstert.2015.04.018.
    1. Corifollitropin Alfa Dose-finding Study Group A randomized dose-response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation. Hum Reprod. 2008;23:2484–2492. doi: 10.1093/humrep/den288.
    1. Corifollitropin alfa Ensure Study Group Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower-body-weight women. Reprod Biomed Online. 2010;21:66–76. doi: 10.1016/j.rbmo.2010.03.019.
    1. Croxtall JD, Mckeage K. Corifollitropin alfa: a review of its use in controlled ovarian stimulation for assisted reproduction. BioDrugs. 2011;25:243–254. doi: 10.2165/11206890-000000000-00000.
    1. Devroey P, Boostanfar R, Koper NP, Mannaerts BM, Ijzerman-Boon PC, Fauser BC, ENGAGE Investigators A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod. 2009;24:3063–3072. doi: 10.1093/humrep/dep291.
    1. Farrag A, Costantini A, Manna C, Grimaldi G. Recombinant HCG for triggering ovulation increases the rate of mature oocytes in women treated for ICSI. J Assist Reprod Genet. 2008;25:461–466. doi: 10.1007/s10815-008-9262-x.
    1. Fatemi HM, Polyzos NP, van Vaerenbergh I, Bourgain C, Blockeel C, Alsbjerg B, Papanikolaou EG, Humaidan P. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril. 2013;100:742–747. doi: 10.1016/j.fertnstert.2013.05.028.
    1. Fauser BC, Alper MM, Ledger W, Schoolcraft WB, Zandvliet A, Mannaerts BM, Engage Investigators Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. Reprod Biomed Online. 2011;22:S23–S31. doi: 10.1016/S1472-6483(11)60006-0.
    1. Galindo A, Bodri D, Guillen JJ, Colodron M, Vernaeve V, Coll O. Triggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: a randomised clinical trial. Gynecol Endocrinol. 2009;25:60–66. doi: 10.1080/09513590802404013.
    1. Griesinger G, Diedrich K, Devroey P, Kolibianakis EM. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update. 2006;12:159–168. doi: 10.1093/humupd/dmi045.
    1. Hernández ER, Gómez-Palomares JL, Ricciarelli E. No room for cancellation, coasting, or ovarian hyperstimulation syndrome in oocyte donation cycles. Fertil Steril. 2009;91:1358–1361. doi: 10.1016/j.fertnstert.2008.03.077.
    1. Humaidan P, Kol S, Papanikolaou EG, Copenhagen GnRH Agonist Triggering Workshop Group GnRH agonist for triggering of final oocyte maturation: time for a change of practice? Hum Reprod Update. 2011;17:510–524. doi: 10.1093/humupd/dmr008.
    1. Humaidan P, Papanikolaou EG, Kyrou D, Alsbjerg B, Polyzos NP, Devroey P, Fatemi HM. The luteal phase after GnRH-agonist triggering of ovulation: present and future perspectives. Reprod Biomed Online. 2012;24:134–141. doi: 10.1016/j.rbmo.2011.11.001.
    1. Jayaprakasan K, Herbert M, Moody E, Stewart JA, Murdoch AP. Hum Fertil. Vol. 10. Camb: 2007. Estimating the risks of ovarian hyperstimulation syndrome (OHSS): implications for egg donation for research; pp. 183–187.
    1. Lutjen P, Trounson A, Leeton J, Findlay J, Wood C, Renou P. The establishment and maintenance of pregnancy using in vitro fertilization and embryo donation in a patient with primary ovarian failure. Nature. 1984;307:174–175. doi: 10.1038/307174a0.
    1. Pacchiarotti A, Selman H, Valeri C, Napoletano S, Sbracia M, Antonini G, Biagiotti G, Pacchiarotti A. Ovarian Stimulation Protocol in IVF: An Up-to-Date Review of the Literature. Curr Pharm Biotechnol. 2016;17:303–315. doi: 10.2174/1389201017666160118103147.
    1. Requena A, Cruz M, Collado D, Izquierdo A, Ballesteros A, Munoz M, Garcia-Velasco JA. Evaluation of the degree of satisfaction in oocyte donors using sustained-release FSH corifollitropin α. Reprod Biomed Online. 2013;26:253–259. doi: 10.1016/j.rbmo.2012.11.015.
    1. Sauer MV, Paulson RJ. Oocyte and embryo donation. Curr Opin Obstet Gynecol. 1995;7:193–198. doi: 10.1097/00001703-199506000-00007.
    1. Shapiro BS, Daneshmand ST, Garner FC, Aguirre M, Ross R. Comparison of human chorionic gonadotropin and gonadotropin-releasing hormone agonist for final oocyte maturation in oocyte donor cycles. Fertil Steril. 2007;88:237–239. doi: 10.1016/j.fertnstert.2006.11.069.
    1. Youssef MA, Abdelmoty HI, Ahmed MA, Elmohamady M. GnRH agonist for final oocyte maturation in GnRH antagonist co-treated IVF/ICSI treatment cycles: Systematic review and meta-analysis. J Adv Res. 2015;6:341–349. doi: 10.1016/j.jare.2015.01.005.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner